Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

US12275706B2 · kind B2 · utility

Assignee

• Exelixis, Inc. · US

Inventors

• Adrian St. Clair Brown · Harlow, GB
• Peter Lamb · Oakland, US
• William P. Gallagher · Princeton, US

Key dates

• Filing date: Nov 25, 2024
• Grant date: Apr 15, 2025
• Expiry date: Nov 25, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D215/233
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-ffuorophenyl)cyclopropane-1,1-dicarboxamide.